You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma
SBC: NUVOX PHARMA, L.L.C. Topic: 102Glioblastoma multiforme (GBM) is a malignant primary brain tumor affecting about 12,000 new cases per year in the U.S. Average survival is only about 14-15 months. Radiation (RT) is most commonly administered as 30 fractions of 2 Gray each over 6-weeks with concomitant temozolomide (TMZ). GBM tumors are hypoxic. The primary mechanism of RT is creation of singlet oxygen; hypoxia within GBM adversel ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
An Integrated Microarray Printing and Detection System
SBC: BIOSENSING INSTRUMENT INC Topic: 400DESCRIPTIONprovided by applicantMicroarray technology has dramatically advanced the study of protein interactions leading to discovery and validation of new biomarkers and therapeutic drugsTypicallyprotein microarrays are pre spotted with target molecules in one device and then tested with probe molecules using another deviceDuring each testing cyclethe entire microarray becomes exposed to the pro ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
New Technologies for Therapist Training and Patient Engagement in Behavioral Parent Training
SBC: KOBAK, KENNETH A Topic: 104Project Summary Abstract Behavioral parent trainingBPTis the gold standard treatment for disruptive behavior in preschool and elementary school age childrenDespite clear empirical evidence that it is effectiveadoption rates by practitioners remains woefully low due in part to a shortage of clinicians trained in BPTIn additioneven when BPT is administeredit is often done incorrectlyThe current stud ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Stable Gene Transfer by RNA Delivery
SBC: B-MoGen Biotechnologies Inc Topic: NHLBIAbstract Non viral gene delivery is used in most biomedical laboratories for basic research and for many commercial and medical applications These include basic investigations into gene function modification of cells for the production of recombinant proteins and generation of genetically modified human cells for cancer therapy e g chimeric antigen receptor transgenic T cells However the d ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Biomaterials for mRNA based cellular reprogramming
SBC: STEM PHARM, INCORPORATED Topic: 100Project Summary Abstract Induced pluripotent stem cells iPSCs hold great promise in the areas of disease modeling and regenerative medicine and as a result have unique commercial potential There are currently more than ongoing clinical trials in stem cell therapies including the first in human trial using human iPSC derived retinal pigment epithelial cells to treat ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Disaggregation of Toxic Protein Oligomers in Brain with Electromagnetic Treatment
SBC: NeuroEM Therapeutics, Inc. Topic: 104ABSTRACT Formation of misfolded protein oligomers in neurons is an early and causative event in a variety of neurodegenerative diseases such as Alzheimer s Disease amyloid and tau oligomers Fronto temporal lobe dementia tau oligomers and Parkinson s Disease synuclein oligomers These toxic oligomers share a common aggregation mechanism that involves formation of hydrogen bonds betwee ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
OpenBeds: Improving the Delivery of Care for Patients with Drug Addiction
SBC: Openbeds Inc. Topic: NIDAThere is an urgent need for more effective mechanisms that leverage current technologies and best practices to both identify capacity and refer patients to drug treatment facilitiesThe applicant organizationOpenBeds Incis partnering with the non profit MESH Coalitionthree of the largest health care systems offering drug treatment in Indiana and the Indiana Division of Mental Health and AddictionDM ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomics' reduced genome E coli strains
SBC: SCARAB GENOMICS, LLC Topic: NIAIDScarab Genomics goal is to commercialize carrier proteins for conjugate vaccine manufacture This proposal focuses on two bacterial carrier proteins that have been approved by the FDA and that are in use in pre clinical and clinical studies Exoprotein A EPA from Pseudomonas aeruginosa and Protein D PD from non typeable Haemophilus influenzae These proteins are difficult to make by the conve ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Gaze Steered Microphone Array for Understanding Speech in Noisy Areas
SBC: ADVANCED MEDICAL ELECTRONICS CORP Topic: YProject Summary Abstract Advanced Medical ElectronicsAMEproposes the development of a novel portable wireless hearing aid accessory that utilizes head pose and eye tracking of the hearing aid user to steer a microphone array in the direction of interestA common problem for hearing aid users is the difficulty of participating in conversations in a noisy environment such as at a workplace or restaur ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Tools for Accelerating R&D for Historically Understudied Protein Kinases
SBC: LUCEOME BIOTECHNOLOGIES, L.L.C. Topic: NCATSProtein kinases are central players in almost every aspect of human physiology and serve as critical mediators of signal transductionThe dysfunction of many kinases is implicated in cancerdiabetesinflammationand cardiovascular diseases and many are validated targets for therapeutic interventionThe human genome encodesprotein kinasesYettheor so marketed protein kinase drugstarget only a small fract ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health